

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p align="center">Licensee</p> <p>1. Hospital San Cristóbal</p> <p>2. P.O. Box 800501 Coto Laurel Ponce, PR 00780-0501</p>	<p>In accordance with email dated June 17, 2019.</p> <p>3. License number: 52-25232-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: September 30, 2023</p> <p>5. Docket No.: 030-33026 Reference No.:</p>																		
<table border="0"> <tr> <td data-bbox="142 806 472 888">6. Byproduct, source, and/or special nuclear material</td> <td data-bbox="525 806 924 834">7. Chemical and/or physical form</td> <td data-bbox="1018 806 1396 888">8. Maximum amount that licensee may possess at any one time under this license</td> <td data-bbox="1428 806 1963 834">9. Authorized use</td> </tr> <tr> <td data-bbox="142 930 472 1020">A. Any byproduct material permitted by 10 CFR 35.100</td> <td data-bbox="525 930 924 958">A. Any</td> <td data-bbox="1018 930 1396 958">A. As Needed</td> <td data-bbox="1428 930 1963 1020">A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</td> </tr> <tr> <td data-bbox="142 1037 472 1128">B. Any byproduct material permitted by 10 CFR 35.200</td> <td data-bbox="525 1037 924 1065">B. Any</td> <td data-bbox="1018 1037 1396 1065">B. As Needed</td> <td data-bbox="1428 1037 1963 1095">B. For use in imaging and localization studies permitted by 10 CFR 35.200.</td> </tr> <tr> <td data-bbox="142 1144 472 1235">C. Any byproduct material permitted by 10 CFR 35.300</td> <td data-bbox="525 1144 924 1172">C. Any</td> <td data-bbox="1018 1144 1396 1172">C. 350 millicuries total</td> <td data-bbox="1428 1144 1963 1260">C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</td> </tr> <tr> <td data-bbox="142 1276 472 1334">D. Iodine-125 permitted by 10 CFR 35.400</td> <td data-bbox="525 1276 924 1334">D. Sealed Sources (Theragenics I-seed, Model AgX100)</td> <td data-bbox="1018 1276 1396 1305">D. 4 curies total</td> <td data-bbox="1428 1276 1963 1400">D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</td> </tr> </table>	6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use	A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.	B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.	C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 350 millicuries total	C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.	D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Theragenics I-seed, Model AgX100)	D. 4 curies total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use																	
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.																	
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.																	
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 350 millicuries total	C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.																	
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Theragenics I-seed, Model AgX100)	D. 4 curies total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.																	

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-25232-01Docket or Reference Number
030-33026

Amendment No. 7

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at Hospital San Cristóbal, Puerto Rico Highway 506, Coto Laurel, Puerto Rico.
11. The Radiation Safety Officer (RSO) for this license is Carmelo Pérez.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized Users</u> | <u>Material and Use</u> |
|------------------------------------|---|
| Carlos Remedios, M.D. | 10 CFR 35.400 |
| Ricardo E. Santiago Montalvo, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
| Miguel A. Serpa, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-25232-01Docket or Reference Number
030-33026

Amendment No. 7

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 20, 1992 (ML031490315)
 - B. Application dated December 20, 2002 (ML023640441)
 - C. Letter dated July 18, 2006 (ML062070211)
 - D. Letter dated August 2, 2006 (ML062190431)
 - E. Letter dated June 17, 2019 (ML19178A298)

Date: August 27, 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Farrah Gaskins
Region 1